I dont expect much news from chk1. Except. Who they may be doing a combo trial with which should get filed this year and may trigger an additional milestone to us. News that may be coming though... Preclinical poc trials have been done in MS. RA. IBS. But none has been published or presented at conferences. Psoriasis was however. And we know these trials were succesful and grant funded so i expect we may see somethings published. Further innovate uk finding on tyk2 in t-all. SEPSIS is a gap. It was one of 2 drivers for SRI researching tyk2 in the first place. Kills 200k people pa in the states. And gets a lot of funding from the department if defence both for battlefield medicine. And black funding for protecting civilians against bioterror. Curiously silent on this. So i think much of the newsflow will be Tyk2 related. Imho etc
Very true Potnak, however the stipulation for trial was IIRC a 'minimum' of 3 months life expectancy.
Also the first to be dosed will be at smaller scales and built up over time for subsequent trialists.
Something worth noting is that if someone is right on the cusp of eligibility I don't think they would be part of any early dosing. With such a short prognosis they won't risk their trial or data. As you say, IF there were early great results it would get out. If someone was part of dose escalation and the worst happened it all sits as a negative for any data. I don't mean that to sound harsh.
Yes, P1 is just for toxicity but don't forget, the patients being enrolled on the trials only have months to live. If there is any change in their prognosis, it will get out, whether officially or not. Not sure if the first dose had been given yet but I'd expect a good news RNS around 12 weeks after that, maybe a milestone reached too.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.